Myriad Genetics and MD Anderson partner to evaluate molecular residual disease assay

The University of Texas MD Anderson Cancer Center and Myriad Genetics, Inc. today announced a five-year strategic alliance to accelerate the clinical evaluation and development of Myriad’s molecular residual disease (MRD) assay.

SpaceX CRS-31 supports heart health, neurodegeneration, and student science

More than 25 payloads sponsored by the International Space Station (ISSInternational Space Station) National Laboratory, including technology demonstrations, in-space manufacturing, student experiments, and multiple projects

November 4, 2024

Understanding innate-like T cells for enhanced immunotherapy

Our immune system spans two worlds-;innate and adaptive. Innate immune cells are like troops at the gate ready to hold off invaders and raise the

September 24, 2024

Newly identified genes may hold the key to understanding brain’s response to PFAS

Per- and polyfluorinated alkyl substances (PFAS) earn their “forever chemical” moniker by persisting in water, soil and even the human brain.

January 7, 2025

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.